Recent News

• 07.16.2026 - Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
• 05.13.2026 - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
• 04.15.2026 - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
• 03.23.2026 - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
• 03.03.2026 - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
• 11.13.2025 - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.07.2025 - Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 07.16.2026 - 8-K Current report
• 07.16.2026 - EX-99.1 EX-99.1
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.27.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - 8-K Current report
• 05.13.2026 - EX-99.1 EX-99.1